AMENDMENTS TO THE CLAIMS

1. (Currently Amended) A compound~~benzenesulfonamide derivative~~ of the formula (I), its tautomeric or stereoisomeric form, or a salt thereof:



(I)

wherein

X represents O or S;

R^1 represents hydrogen, halogen, hydroxy, nitro, cyano, C_{1-6} alkoxy carbonyl, amino, C_{1-6} alkylamino, di(C_{1-6} alkyl)amino, C_{1-6} alkanoyl, phenyl, C_{1-6} alkyl optionally substituted by mono-, di- or tri- halogen, or C_{1-6} alkoxy optionally substituted by mono-, di- or tri- halogen;

R^2 represents hydrogen, halogen, hydroxy, nitro, cyano, C_{1-6} alkoxy carbonyl, amino, C_{1-6} alkylamino, di(C_{1-6} alkyl)amino, C_{1-6} alkanoyl, phenyl, C_{1-6} alkyl optionally substituted by mono-, di- or tri- halogen, or C_{1-6} alkoxy optionally substituted by mono-, di- or tri- halogen;

R^3 represents hydrogen, halogen, hydroxy, nitro, cyano, amino, carboxy, tetrazolyl, C_{1-6} alkoxy, C_{1-6} alkoxycarbonyl, C_{1-6} alkanoyl, C_{1-6} alkanoylamino, C_{1-6} alkyl optionally substituted by mono-, di- or tri- halogen or hydroxy;

R^4 represents











or



wherein:

~~R^{40} represents C_{1-6} alkyl substituted by pyrrolidinyl or piperidinyl wherein said pyrrolidinyl and piperidinyl are optionally substituted by mono- or di- oxo, 7-oxa-bicyclo[4.1.0]hept-3-yl optionally having 1 or 2 substituents selected from the group consisting of amino, (C_{1-6} alkyl)amino and di(C_{1-6} alkyl)amino, or a 5 to 8 membered saturated heterocyclic ring containing 1 or 2 heteroatoms selected from the group consisting of N and O and optionally having from 1 to 3 substituents selected from the group consisting of hydroxy, amino, oxo and C_{1-6} alkyl;~~

R^{41} represents hydrogen, C_{1-6} alkyl optionally substituted by amino, C_{1-6} alkylamino, di(C_{1-6} alkyl)amino, or 2,5-dioxopyrrolidin-1-yl, or a C_{5-8} cycloalkyl optionally substituted by hydroxy,

or

R^{40} and R^{41} may form, together with adjacent N atom, a 5-to-8-membered saturated heterocyclic ring optionally interrupted by NH or O, wherein said 5-to-8 membered saturated heterocyclic ring is substituted by mono- or di-oxo;

R^{42} represents C_{1-6} alkylene optionally substituted by hydroxy or carboxy, or a C_{5-8} cycloalkyl substituted by at least one hydroxy and moreover optionally 1 or 2 substituents selected from the group consisting of hydroxy, amino, oxo and C_{1-6} alkyl,

or

R^{41} and R^{42} may form, together with adjacent N atom, a 5-to-8-membered saturated heterocyclic ring optionally interrupted by NH or O, wherein said 5-to-8 membered saturated heterocyclic ring is substituted by mono- or di-oxo;

with the proviso that when R^{41} is hydrogen, C_{1-6} alkyl optionally substituted by amino, C_{1-6} alkylamino or di(C_{1-6} alkyl)amino R^{42} is hydroxy substituted C_{1-6} alkylene or carboxy substituted C_{1-6} alkylene,

R^{43} represents hydrogen, or C_{1-6} alkyl optionally substituted by hydroxy or carboxy,

R^{44} represents hydrogen or C_{1-6} alkyl optionally substituted by hydroxy or carboxy,

with the proviso that when R^{41} and R^{42} form together with adjacent N atom a 5-to-8 membered saturated heterocyclic ring substituted by mono- or di-oxo, R^{44} represents hydroxy substituted C_{1-6} alkyl or carboxy substituted C_{1-6} alkyl,

R^{45}, R^{47}, R^{49} and R^{50} independently represent hydrogen or C_{1-6} alkyl,

R^{46} and R^{48} independently represent C_{1-6} alkylene optionally substituted hydroxy or carboxy,

n represents an integer selected from 1 to 3,

m represents an integer selected from 0 to 3;

R^{51} represents hydrogen, C_{1-6} alkyl, or a 3-to-8-membered saturated ring optionally interrupted by NH or O,

R^{52} represents hydrogen C_{1-6} alkoxy carbonyl or C_{1-6} alkyl substituted by

~~carboxy, amino, N-(C_{1-6}-alkylsulfonyl)amino, N-(C_{1-6}-alkanoyl)amino, C_{1-6} alkoxycarbonyl, tetrazolyl, triazolyl, indolinyl, isoindolinyl, indolyl, isoindolyl, pyrrolidinyl optionally substituted by mono- or di- oxo, or piperidinyl optionally substituted by mono- or di- oxo;~~

~~with the proviso that when R^{51} and R^{52} are hydrogen at the same time, R^3 is tetrazolyl or C_{1-6}-alkanoyl, or when R^{51} is hydrogen or C_{1-6}-alkyl, R^{52} is other than hydrogen;~~

~~R^{61} and R^{62} independently represent hydrogen or C_{1-6}-alkyl optionally substituted by hydroxy, carboxy, phenyl or mono-, di- or tri-halogen;~~

R^{71} represents hydrogen, or C_{1-6} alkyl optionally substituted by amino, hydroxy, carboxy, pyrrolidinyl or piperidinyl, wherein said pyrrolidinyl and piperidinyl are optionally substituted by mono- or di- oxo;

R^{72} represents hydrogen, carboxy, C_{1-6} alkanoyl, amino, (C_{1-6}alkyl)amino, di(C_{1-6} alkyl) amino, N-(C_{1-6}alkyl)amino carbonyl, C_{1-6} alkyl optionally substituted by hydroxy, carboxy, or mono-, di- or tri- halogen, C_{1-6} alkoxy optionally substituted by mono-, di- or tri- halogen, pyrrolidinyl or piperidinyl, wherein said pyrrolidinyl and piperidinyl are optionally substituted by mono- or di- oxo;

Z^1 represents $-[CH_2]_p-$, wherein p represents an integer 1 or 2;

R^{81} represents hydrogen, C_{1-6} alkoxycarbonyl, or C_{1-6} alkyl substituted by pyrrolidinyl or piperidinyl, wherein said pyrrolidinyl and piperidinyl are optionally substituted by mono- or di- oxo;

R^{82} represents hydrogen, hydroxy, carboxy or C_{1-6} alkyl substituted by hydroxy, amino, or carboxy,

R^{83} represents hydrogen, hydroxy, carboxy or C_{1-6} alkyl substituted by hydroxy, amino, or carboxy,

with the proviso that when R^{81} is hydrogen, R^{82} or R^{83} is other than hydrogen;

Z^2 represents $-[CH_2]_q-$, wherein q represents an integer selected from 0 to 3;

~~R^{91} represents hydrogen or C_{1-6}-alkyl optionally substituted by phenyl;~~

~~R^{111} represents hydrogen, carboxy, C_{1-6}-alkoxy carbonyl, C_{1-6}-alkanoyl, N-(C_{1-6}alkyl) aminocarbonyl, C_{1-6}-alkoxy optionally substituted by mono-, di- or tri- halogen, or C_{1-6}-alkyl optionally substituted by hydroxy, mono-, di- or tri-halogen, amino, (C_{1-6}-alkyl)amino, di(C_{1-6}-alkyl)amino, N-(C_{1-6}-alkyl sulfonyl)amino, N-(C_{1-6}-alkanoyl)amino, C_{1-6}-alkoxycarbonyl, tetrazolyl,~~

~~triazolyl, indolinyl, isoindolinyl, indolyl, isoindolyl, pyrrolidinyl or piperidinyl wherein said pyrrolidinyl and piperidinyl are optionally substituted by mono- or di- oxo;~~

A ring represents a 3 to 8 membered saturated heterocyclic ring, in which the nitrogen atom N^A is the only hetero atom; and

B ring represents a 3 to 8 membered saturated heterocyclic ring, in which the nitrogen atom N^B is the only hetero atom;

~~C ring and D ring together form a 7 to 15 membered diazabicycliccyclic ring; and~~

~~E ring represents a 5 to 8 membered saturated heterocyclic ring, in which the nitrogen atom N^E is the only hetero atom~~.

2. (Currently Amended) The compound~~benzenesulfonamide derivative~~ of the formula (I), its tautomeric or stereoisomeric form, or a salt thereof as claimed in claim 1, wherein R^4 represents











,


,


,


or



,



wherein:

~~R^{40} represents C_{1-6} alkyl having a substituent selected from the group consisting of 2-oxo-pyrrolidin-1-yl, and 2,5-dioxo-pyrrolidin-1-yl, 2-oxo-piperidin-1-yl, 2-oxo-piperidin-3-yl, 4-oxo-piperidin-1-yl, 2-oxo-piperidin-6-yl, 2,5-dioxo-piperidin-1-yl, 2,6-dioxo-piperidin-1-yl, and 2,6-dioxo-piperidin-3-yl, piperidin-1-yl, -2-yl, -3-yl or -4-yl (wherein said piperidin is optionally substituted by mono- or di- oxo),~~

~~hexahydroazepin-1-yl, 2-yl, 3-yl or 4-yl (wherein said hexahydroazepin is optionally substituted by mono- or di- oxo), and 7-oxa-bicyclo[4.1.0]hept-3-yl optionally substituted by amino;~~

~~R^{41} represents hydrogen, cyclopentyl or C_{1-6} alkyl optionally substituted by amino, C_{1-6} alkyl amino, di-(C_{1-6} alkyl)amino, or 2,5- dioxo-pyrrolidin-1-yl,;~~

~~R^{42} represents C_{1-4} alkylene substituted by carboxy or cyclohexyl substituted by mono- or di hydroxy,;~~

~~R^{41} and R^{42} may form, together with adjacent N atom, a 5 or 6 membered saturated heterocyclic ring;~~

~~with the proviso that when R^{41} is hydrogen, C_{1-6} alkyl optionally substituted by amino, C_{1-6} alkylamino, or di(C_{1-6} alkyl)amino, R^{42} is hydroxy substituted C_{1-6} alkylene or carboxy substituted C_{1-6} alkylene;~~

~~R^{43} represents hydrogen or C_{1-6} alkyl optionally substituted by hydroxy,;~~

~~R^{44} represents C_{1-6} alkyl optionally substituted by hydroxy or carboxy,;~~

~~with the proviso that when R^{41} and R^{42} form, together with adjacent N atom, a 5 or 6 membered saturated heterocyclic ring, R^{44} is hydroxy substituted C_{1-6} alkyl or carboxy substituted C_{1-6} alkyl;~~

~~R^{45}, R^{47}, R^{49} and R^{50} independently represent hydrogen, methyl or ethyl;~~

~~R^{46} and R^{48} independently represent C_{1-6} alkylene optionally substituted hydroxy or carboxy;~~

~~R^{51} represents hydrogen, cyclopentyl, ethyl or methyl;~~

~~R^{52} represents methoxycarbonyl or C_{1-6}alkyl substituted by methoxycarbonyl, methanesulfonylamino, acetamido, indolyl, tetrazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, 1,2,5-triazolyl, 1,3,4-triazolyl, pyrrolidin-1-yl, 2-oxo pyrrolidin-1-yl, 2,5- dioxopyrrolidin-1-yl, 2-oxo-piperidin-1-yl, 2-oxo-piperidin-3-yl, 4-oxo-piperidin-1-yl, 2-oxo-piperidin-6-yl, 2,5-dioxo-piperidin-1-yl, 2,6- dioxo-piperidin-1-yl, or 2,6-dioxo-piperidin-3-yl;~~

~~R^{61} and R^{62} independently represents benzyl or phenethyl;~~

R^{72} represents hydrogen, carboxy, C_{1-6} alkanoyl, amino, (C_{1-6}alkyl)amino, di(C_{1-6}alkyl)amino, N-(C_{1-6}alkyl)amino carbonyl, C_{1-6} alkyl optionally substituted by hydroxy, carboxy, or mono-, di- or tri- halogen, C_{1-6} alkoxy optionally substituted by mono-, di- or tri- halogen, pyrrolidinyl or piperidinyl wherein said pyrrolidinyl and piperidinyl are optionally substituted by mono-

or di- oxo;

R^{81} represents hydrogen, methoxycarbonyl or C_{1-6} alkyl substituted by 2-oxo-pyrrolidin-1-yl, 2,5- dioxo-pyrrolidin-1-yl 2-oxo-piperidin-1-yl, 2-oxo-piperidin-3-yl, 4-oxo-piperidin-1-yl, 2-oxo-piperidin-6-yl, 2,5-dioxo-piperidin-1-yl, 2,6-dioxo-piperidin-1-yl, or 2,6-dioxo-piperidin-3-yl;

R^{82} represents hydrogen, hydroxy or hydroxy substituted C_{1-6} alkyl; and

R^{83} represents hydrogen, hydroxy or carboxy;

with the proviso that when R^{82} and R^{83} are hydrogen at the same time, R^{81} is other than hydrogen, or when R^{81} and R^{83} are hydrogen at the same time, R^{82} is other than hydrogen~~; and~~

~~R^{91} represents benzyl or phenethyl~~.

3. (Currently Amended) The compound~~benzenesulfonamide derivative~~ of claim 1, wherein the derivative is of the formula (I-b), its tautomeric or stereoisomeric form, or a salt thereof:



(I-b)

wherein:

R^1 represents fluoro, chloro, bromo, iodo, or nitro;

R^2 represents fluoro, chloro, bromo, iodo, or nitro;

R^3 represents acetyl, cyano, or tetrazolyl;

R^4 represents











or



wherein:

~~R^{40} represents C_{1-6}-alkyl substituted by pyrrolidinyl or piperidinyl wherein said pyrrolidinyl and piperidinyl are optionally substituted by mono- or di- oxo, 7-oxa-bicyclo[4.1.0]hept-3-yl optionally having 1 or 2 substituents selected from the group consisting of amino, (C_{1-6}-alkyl)amino and di(C_{1-6}-alkyl)amino, or a 5 to 8 membered saturated heterocyclic ring containing 1 or 2 heteroatoms selected from the group consisting of N and O and optionally having from 1 to 3 substituents selected from the group consisting of hydroxy, amino, oxo and C_{1-6}-alkyl;~~

~~R^{41} represents hydrogen, C_{1-6}-alkyl optionally substituted by amino, C_{1-6} alkylamino, di(C_{1-6}-alkyl)amino, or 2,5-dioxo-pyrrolidin-1-yl, or a C_{5-8}-cycloalkyl optionally substituted by hydroxy,;~~

~~or~~

~~R^{40} and R^{41} may form, together with adjacent N atom, a 5 to 8 membered saturated heterocyclic ring optionally interrupted by O;~~

~~R^{42} represents C_{1-6} alkylene optionally substituted by hydroxy or carboxy, or a C_{5-8} cycloalkyl substituted by at least one hydroxy and moreover optionally 1 or 2 substituents selected from the group consisting of hydroxy, amino, oxo and C_{1-6} alkyl,;~~

~~or~~

~~R^{41} and R^{42} may form, together with adjacent N atom, a 5 to 8 membered saturated heterocyclic ring optionally interrupted by NH or O, wherein said 5 to 8 membered saturated heterocyclic ring is substituted by mono- or di- oxo,;~~

~~with the proviso that when R^{41} is hydrogen, C_{1-6} alkyl optionally substituted by amino, C_{1-6} alkylamino, or di(C_{1-6} alkyl)amino, R^{42} is hydroxy substituted C_{1-6} alkylene or carboxy substituted C_{1-6} alkylene;~~

~~R^{43} represents hydrogen, or C_{1-6} alkyl optionally substituted by hydroxy or carboxy;~~

~~R^{44} represents C_{1-6} alkyl optionally substituted by hydroxy or carboxy,;~~

~~with the proviso that when R^{41} and R^{42} form, together with adjacent N atom, a 5 to 8 membered saturated heterocyclic ring substituted by mono- or di- oxo, R^{44} represents hydroxy substituted C_{1-6} alkyl or carboxy substituted C_{1-6} alkyl;~~

~~R^{45}, R^{47}, R^{49} and R^{50} independently represent hydrogen or C_{1-6} alkyl;~~

~~R^{46} and R^{48} independently represent C_{1-6} alkylene optionally substituted hydroxy or carboxy;~~

~~n represents an integer selected from 1 to 3;~~

~~m represents an integer selected from 0 to 3;~~

~~R^{51} represents hydrogen, C_{1-6} alkyl, or a 3 to 8 membered saturated ring optionally interrupted by NH or O;~~

~~R^{52} represents hydrogen, C_{1-6} alkoxy carbonyl, or C_{1-6} alkyl substituted by N (C_{1-6} alkylsulfonyl)amino, N (C_{1-6} alkanoyl)amino, C_{1-6} alkoxycarbonyl, tetrazolyl, triazolyl, indolinyl, isoindolinyl, indolyl, isoindolyl, or pyrrolidinyl optionally substituted by mono- or di- oxo, or piperidinyl optionally substituted by mono- or di- oxo;~~

~~with the proviso that when R^{51} and R^{52} are hydrogen at the same time, R^{3} is tetrazolyl or C_{1-6} alkanoyl, or when R^{51} is hydrogen or C_{1-6} alkyl, R^{52} is other than hydrogen;~~

~~R^{61} and R^{62} independently represent hydrogen or C_{1-6} alkyl optionally substituted by hydroxy, carboxy, phenyl or mono-, di- or tri- halogen;~~

R^{71} represents hydrogen, or C_{1-6} alkyl optionally substituted by amino, hydroxy, carboxy, pyrrolidinyl or piperidinyl, wherein said pyrrolidinyl and piperidinyl are optionally substituted by mono- or di- oxo;

R^{72} represents hydrogen, carboxy, C_{1-6} alkanoyl, amino, (C_{1-6}alkyl)amino, di(C_{1-6}alkyl)amino, N-(C_{1-6}alkyl)amino carbonyl, C_{1-6} alkyl optionally substituted by hydroxy, carboxy, or mono-, di- or tri- halogen, C_{1-6} alkoxy optionally substituted by mono-, di- or tri- halogen, pyrrolidinyl or piperidinyl, wherein said pyrrolidinyl and piperidinyl are optionally substituted by mono- or di- oxo;

Z^1 represents $-[CH_2]_p-$, wherein p represents an integer 1 or 2;

R^{81} represents hydrogen, C_{1-6} alkoxycarbonyl, or C_{1-6} alkyl substituted by pyrrolidinyl, or piperidinyl, wherein said pyrrolidinyl and piperidinyl are optionally substituted by mono- or di- oxo;

R^{82} represents hydrogen, hydroxy, carboxy or C_{1-6} alkyl substituted by hydroxy, amino, or carboxy,

R^{83} represents hydrogen, hydroxy, carboxy or C_{1-6} alkyl substituted by hydroxy, amino, or carboxy,

with the proviso that when R^{81} is hydrogen, R^{82} or R^{83} is other than hydrogen;

Z^2 represents $-[CH_2]_q-$,

wherein

q represents an integer selected from 0 to 3;

~~R^{91} represents hydrogen or C_{1-6} alkyl optionally substituted by phenyl;~~

~~R^{111} represents hydrogen, carboxy, C_{1-6} alkoxy carbonyl, C_{1-6} alkanoyl, N-(C_{1-6}alkyl) aminocarbonyl, C_{1-6} alkoxy optionally substituted by mono-, di- or tri- halogen, or C_{1-6} alkyl optionally substituted by hydroxy, mono-, di- or tri- halogen, amino, (C_{1-6} alkyl)amino, di(C_{1-6} alkyl)amino, N-(C_{1-6} alkyl sulfonyl)amino, N-(C_{1-6} alkanoyl)amino, C_{1-6} alkoxycarbonyl, tetrazolyl, triazolyl, indolinyl, isoindolinyl, indolyl, isoindolyl, pyrrolidinyl or piperidinyl wherein said pyrrolidinyl and piperidinyl are optionally substituted by mono- or di- oxo;~~

A ring represents a 3 to 8 membered saturated heterocyclic ring, in which the nitrogen

atom N^A is the only hetero atom; and

B ring represents a 3 to 8 membered saturated heterocyclic ring, in which the nitrogen atom N^B is the only hetero atom;

~~C ring and D ring together form a 7 to 15 membered diazabicycliccyclic ring; and~~

~~E ring represents a 5 to 8 membered saturated heterocyclic ring, in which the nitrogen atom N^E is the only hetero atom~~.

4. (Currently Amended) The compound~~benzenesulfonamide derivative~~ of claim 3~~formula (I-b)~~, its tautomeric or stereoisomeric form, or a salt

wherein:

R^1 represents fluoro, chloro or bromo;

R^2 represents fluoro, chloro or bromo;

R^3 represents cyano;

R^4 represents








R81
N
N
R82
R83

,


R81
N
N
R82
R83

,


R81
N
R82
N
R83

,


R81
N
N
R82
R83

,


N
R82
N
R81
R83

,


R83
N
N

,


R83
N
N
R81
N
N
N
H

,

,





wherein:

~~R^{40} represents C_{1-6} alkyl having a substituent selected from the group consisting of 2-oxo-pyrrolidin-1-yl, and 2,5-dioxo-pyrrolidin-1-yl, 2-oxo-piperidin-1-yl, 2-oxo-piperidin-3-yl, 4-oxo-piperidin-1-yl, 2-oxo-piperidin-6-yl, 2,5-dioxo-piperidin-1-yl, 2,6-dioxo-piperidin-1-yl, and 2,6-dioxo-piperidin-3-yl, piperidin-1-yl, -2-yl, -3-yl or -4-yl (wherein said piperidin is optionally substituted by mono- or di- oxo), hexahydroazepin-1-yl, -2-yl, -3-yl or -4-yl (wherein said hexahydroazepin is optionally substituted by mono- or di-oxo), and 7-oxa-bicyclo[4.1.0]hept-3-yl optionally substituted by amino;~~

~~R^{41} represents hydrogen, cyclopentyl or C_{1-6} alkyl optionally substituted by amino, C_{1-6} alkyl amino, di-(C_{1-6} alkyl)amino, or 2,5-dioxo-pyrrolidin-1-yl,;~~

~~R^{42} represents C_{1-4} alkylene substituted by carboxy or cyclohexyl substituted by mono or di hydroxy,~~

~~R^{41} and R^{42} may form, together with adjacent N atom, a 5 or 6 membered saturated heterocyclic ring;~~

~~with the proviso that when R^{41} is hydrogen, C_{1-6} alkyl optionally substituted by amino, C_{1-6} alkylamino, or di(C_{1-6} alkyl)amino, R^{42} is hydroxy substituted C_{1-6} alkylene or carboxy substituted C_{1-6} alkylene;~~

~~R^{43} represents hydrogen or C_{1-6} alkyl optionally substituted by hydroxy,;~~

~~R^{44} represents C_{1-6} alkyl optionally substituted by hydroxy or carboxy,;~~

~~with the proviso that when R^{41} and R^{42} form, together with adjacent N atom, a 5 or 6 membered saturated heterocyclic ring, R^{44} is hydroxy substituted C_{1-6} alkyl or carboxy substituted C_{1-6} alkyl;~~

~~R^{45}, R^{47}, R^{49} and R^{50} independently represent hydrogen, methyl or ethyl;~~

~~R^{46} and R^{48} independently represent C_{1-6} alkylene optionally substituted hydroxy or carboxy;~~

~~R^{51} represents hydrogen, cyclopentyl, ethyl or methyl;~~

~~R^{52} represents methoxycarbonyl or C_{1-6}alkyl substituted by methoxycarbonyl, methanesulfonylamino, acetamido, indolyl, tetrazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, 1,2,5-triazolyl, 1,3,4-triazolyl, pyrrolidin-1-yl, 2-oxo pyrrolidin-1-yl, 2,5- dioxo-pyrrolidin-1-yl, 2-oxo-piperidin-1-yl, 2-oxo-piperidin-3-yl, 4-oxo-piperidin-1-yl, 2-oxo-piperidin-6-yl, 2,5-dioxo-piperidin-1-yl, 2,6- dioxo-piperidin-1-yl, or 2,6-dioxo-piperidin-3-yl;~~

~~R^{61} and R^{62} independently represents benzyl or phenethyl;~~

R^{72} represents hydrogen, carboxy, C_{1-6} alkanoyl, amino, (C_{1-6}alkyl)amino, di(C_{1-6}alkyl)amino, N-(C_{1-6}alkyl)amino carbonyl, C_{1-6} alkyl optionally substituted by hydroxy, carboxy, or mono-, di- or tri- halogen, C_{1-6} alkoxy optionally substituted by mono-, di- or tri- halogen, pyrrolidinyl or piperidinyl wherein said pyrrolidinyl and piperidinyl are optionally substituted by mono- or di- oxo;

R^{81} represents hydrogen, methoxycarbonyl or C_{1-6} alkyl substituted by 2-oxo-pyrrolidin-1-yl, 2,5- dioxo-pyrrolidin-1-yl, or 2-oxo-piperidin-1-yl, 2-oxo-piperidin-3-yl, 4-oxo-piperidin-1-yl, 2-oxo-piperidin-6-yl, 2,5-dioxo-piperidin-1-yl, 2,6-dioxo-piperidin-1-yl, or 2,6-dioxo-piperidin-3-yl;

R^{82} represents hydrogen, hydroxy or hydroxy substituted C_{1-6} alkyl; and

R^{83} represents hydrogen, hydroxy or carboxy;

with the proviso that when R^{82} and R^{83} are hydrogen at the same time, R^{81} is other than hydrogen, or when R^{81} and R^{83} are hydrogen at the same time, R^{82} is other than hydrogen~~; and~~

~~R^{91} represents benzyl or phenethyl~~.

5. (Currently Amended) ~~The~~ A compound of claim 1 ~~benzenesulfonamide derivative~~, its tautomeric or stereoisomeric form, or a physiologically acceptable salt thereof ~~as~~

~~claimed in any of claims 1 to 4~~, wherein said compound~~benzenesulfonamide derivative of the formula~~ is selected from the group consisting of:

~~3-(1-Benzyl-hexahydro-pyrrolo[3,4-b]pyrrole-5-sulfonyl)-4-(3,5-dichloro-phenoxy)-benzonitrile;~~

~~N-{4-[5-Cyano-2-(3,5-dichloro-phenoxy)-benzenesulfonyl]-piperazin-2-ylmethyl}-methanesulfonamide;~~

~~N-{4-[5-Cyano-2-(3,5-dichloro-phenoxy)-benzenesulfonyl]-piperazin-2-ylmethyl}-acetamide;~~

~~N-{1-[5-Cyano-2-(3,5-dichloro-phenoxy)-benzenesulfonyl]-piperazin-2-ylmethyl}-methanesulfonamide;~~

~~N-{1-[5-Cyano-2-(3,5-dichloro-phenoxy)-benzenesulfonyl]-piperazin-2-ylmethyl}-acetamide;~~

4-(3,5-Dichloro-phenoxy)-3-[(3R)-(2-hydroxy-ethylamino)-pyrrolidine-1-sulfonyl]-benzonitrile;

~~3-(2-Aminomethyl-piperazine-1-sulfonyl)-4-(3,5-dichloro-phenoxy)-benzonitrile dihydrochloride;~~

~~1-[5-Cyano-2-(3,5-dichloro-phenoxy)-benzenesulfonyl]-[1,4]diazepane-2-carboxylic acid methyl ester;~~

~~4-(3,5-Dichloro-phenoxy)-3-[3(S)-(1H-indol-3-ylmethyl)-piperazine-1-sulfonyl]-benzonitrile;~~

~~4-(3,5-Dichloro-phenoxy)-3-[2(S)-(1H-indol-3-ylmethyl)-piperazine-1-sulfonyl]-benzonitrile;~~

~~4-(3,5-Dichloro-phenoxy)-3-[2-(2,5-dioxo-pyrrolidin-1-ylmethyl)-piperazine-1-sulfonyl]-benzonitrile;~~

~~N-{1-[5-Cyano-2-(3,5-dichloro-phenoxy)-benzenesulfonyl]-[1,4]diazepan-2-ylmethyl}-methanesulfonamide;~~

~~1-[4-(3,5-Dichloro-phenoxy)-3-(piperazine-1-sulfonyl)-phenyl]-ethanone;~~

(R)-N-(1-Aza-bicyclo[2.2.2]oct-3-yl)-5-cyano-2-(3,5-dichloro-phenoxy)-benzenesulfonamide;

(S)-N-(1-Aza-bicyclo[2.2.2]oct-3-yl)-5-cyano-2-(3,5-dichloro-phenoxy)-benzenesulfonamide;

4-(3,5-Dichloro-phenoxy)-3-{4-[(2S)-(1-hydroxy-1-methyl-ethyl)-pyrrolidin-1-yl]-piperidine-1-sulfonyl}-benzonitrile;

~~4-(3,5-Dichloro-phenoxy)-3-(3-tetrazol-2-ylmethyl-piperazine-1-sulfonyl)-benzonitrile;~~

~~4-(3,5-Dichloro-phenoxy)-3-(3-[1,2,4]triazol-1-ylmethyl-piperazine-1-sulfonyl)-benzonitrile;~~

~~4-(3,5-Dichloro-phenoxy)-3-(2-[1,2,4]triazol-1-ylmethyl-piperazine-1-sulfonyl)-benzonitrile;~~

5-Cyano-2-(3,5-dichloro-phenoxy)-N-(2-dimethylamino-ethyl)-N-[2-(2,5-dioxo-pyrrolidin-1-yl)-ethyl]-benzenesulfonamide;

~~4-(3,5-Dichloro-phenoxy)-3-[3-(2,5-dioxo-pyrrolidin-1-ylmethyl)-piperazine-1-sulfonyl]-benzonitrile;~~

4-(3,5-Dichloro-phenoxy)-3-[3-(2,5-dioxo-pyrrolidin-1-ylmethyl)-4-pyrrolidin-1-yl-piperidine-1-sulfonyl]-benzonitrile;

4-(3,5-Dichloro-phenoxy)-3-{4-[(2S)-hydroxymethyl-pyrrolidin-1-yl]-piperidine-1-sulfonyl}-benzonitrile;

4-(3,5-Dichloro-phenoxy)-3-{(2S)-[(2S)-hydroxymethyl-pyrrolidin-1-ylmethyl]-pyrrolidine-1-sulfonyl}-benzonitrile;

N-(1-aza-bicyclo[2.2.2]oct-3-yl)-2-(3,5-dichloro-phenylsulfanyl)-5-nitro-benzenesulfonamide~~; and~~

~~4-(3,5-Dichloro-phenoxy)-3-(piperidine-4-sulfonyl)-benzonitrile~~

4-(3,5-dichlorophenoxy)-3-(4-((3S,4S)-3,4-dihydroxypyrrolidin-1-yl)piperidin-1-ylsulfonyl)benzonitrile;

(3'S,5'S)-methyl-1'-(5-cyano-2-(3,5-dichlorophenoxy)phenylsulfonyl)-1,3'-bipyrrolidine-5'-carboxylate;

3-(4-((3S,4S)-3-(tert-butyldimethylsilyloxy)-4-hydroxypyrrolidin-1-yl)piperidin-1-ylsulfonyl)-4-(3,5-dichlorophenoxy)benzonitrile;

4-(3,5-dichlorophenoxy)-3-((3S,3'S,4S)-3,4-dihydroxy-1,3'-bipyrrolidin-1'-ylsulfonyl)benzonitrile;

(S)-1-(1-(5-cyano-2-(3,5-dichlorophenoxy)phenylsulfonyl)piperidin-4-yl)pyrrolidine-2-carboxylic acid;

4-(3,5-dichlorophenoxy)-3-(2-((3-hydroxypyrrolidin-1-yl)methyl)piperidin-1-ylsulfonyl)benzonitrile; and

(R)-5-cyano-2-(3,5-dichlorophenoxy)-N-(2-(2,5-dioxopyrrolidin-1-yl)ethyl)-N-(1-aza-bicyclo[2.2.2]oct-3-yl)benzenesulfonamide.

6. (Currently Amended) A pharmaceutical composition comprising a compound of claim 1~~the benzenesulfonamide derivative of the formula (I)~~, its tautomeric or stereoisomeric form, or a physiologically acceptable salt thereof ~~as claimed in claim 1~~ as an active ingredient.

7. (Currently Amended) The pharmaceutical composition of~~as claimed in~~ claim 6, further comprising one or more pharmaceutically acceptable excipients.

8. (Currently Amended) The pharmaceutical composition of~~as claimed in~~ claim 6, wherein said compound~~benzenesulfonamide derivative of the formula (I)~~, its tautomeric or stereoisomeric form, or a physiologically acceptable salt thereof is a CCR3 antagonist.

9. (Currently Amended) The ~~medicament~~pharmaceutical composition of~~as claimed in~~ claim 6 suitable for the treatment and/or prophylaxis of an inflammatory disorder or disease.

10. (Currently Amended) The pharmaceutical composition of~~as claimed in~~ claim 9, wherein said inflammatory disorder or disease is selected from the group consisting of asthma, rhinitis, allergic diseases, and autoimmune pathologies.

11. (Currently Amended) The pharmaceutical composition of~~as claimed in~~ claim 6 suitable for the treatment or prevention of a disease selected from the group consisting of HIV, lung granuloma, and Alzheimer's diseases.

12. (Currently Amended) A method for treating or preventing a CCR3 related disorder or disease comprising ~~by which comprises~~ administering a compound of claim 1 or its tautomeric or stereoisomeric form, or a physiologically acceptable salt thereof.

13. (Original) The method of claim 12, wherein said disorder or disease is an inflammatory or immunoregulatory disorder or disease.

14. (Original) The method of claim 12, wherein said disorder or disease is selected from the group consisting of asthma, rhinitis, allergic diseases, and autoimmune pathologies.

15. (Original) The method of claim 12, wherein said disorder or disease is selected from the group consisting of HIV, lung granuloma, and Alzheimer's diseases.

16. (Original) The method of claim 12, wherein said benzenesulfonamide derivative, its tautomeric or stereoisomeric form, or a physiologically acceptable salt thereof is formulated with one or more pharmaceutically acceptable excipients.

17. (Currently Amended) A method of controlling an inflammatory or immunoregulatory disorder or disease in humans and animals which comprises administering a CCR3-antagonistically effective amount of at least one compound of~~according to~~ claim 1.

18. (Currently Amended) A method of treating ~~or preventing~~ a CCR3 related disorder or disease comprising ~~by which comprises~~ administering a compound of claim 3 or its tautomeric or stereoisomeric form, or a physiologically acceptable salt thereof.

19. (Currently Amended) A method of treating ~~or preventing~~ a CCR3 related disorder or disease comprising ~~by which comprises~~ administering a compound of claim 4 or its tautomeric or stereoisomeric form, or a physiologically acceptable salt thereof.

20. (New) The pharmaceutical composition of claim 7, wherein the excipient is an inert substance such as a carrier, a diluent, a flavoring agent, a sweetener, a lubricant, a solubilizer, a suspending agent, a binder, a tablet disintegrating agent or an encapsuling agent.

21. (New) The method of claim 16, wherein the excipient is an inert substance such as a carrier, a diluent, a flavoring agent, a sweetener, a lubricant, a solubilizer, a suspending agent, a binder, a tablet disintegrating agent or an encapsuling agent.